Alvimopan (Entereg) for the Treatment of Postoperative Ileus
Alvimopan (Entereg) is an oral, peripherally-acting mu-opioid receptor antagonist used to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection with primary anastomosis.1 Opioids used postoperatively may cause or prolong postoperative ileus...
Gespeichert in:
| Veröffentlicht in: | American family physician 2011-04, Vol.83 (8), p.978-979 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 979 |
|---|---|
| container_issue | 8 |
| container_start_page | 978 |
| container_title | American family physician |
| container_volume | 83 |
| creator | Karuppiah, Sabesan, MD, DFM Farrah, Roberta, PharmD, BCPS |
| description | Alvimopan (Entereg) is an oral, peripherally-acting mu-opioid receptor antagonist used to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection with primary anastomosis.1 Opioids used postoperatively may cause or prolong postoperative ileus. Alvimopan blocks the opioid effect in the gastrointestinal tract without interfering with the central-acting analgesic effects of opioids. Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_elsev</sourceid><recordid>TN_cdi_proquest_journals_864645062</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0002838X11601366</els_id><sourcerecordid>2454416205</sourcerecordid><originalsourceid>FETCH-LOGICAL-e265t-728c4df3c33897cf6a74227fdfef5cb796fc1160d6d543b03a63e3759e5380f33</originalsourceid><addsrcrecordid>eNp1kE9Lw0AUxHNQsFa_w6IXPQQ2-_ZPAiKUUmuhoGAFb2G7eaupaTbubgN-exMq3jw9Bn4zb5iTZEIpZWkO-dtZch7CbpBKZMUkuZs1fb13nW7JzaKN6PH9lljnSfxAsvGo4x7bSJwlzy5E16HXse6RrBo8hIvk1Oom4OXvnSavD4vN_DFdPy1X89k6RSZFTBXLDa8sGIC8UMZKrThjylYWrTBbVUhrskzSSlaCw5aCloCgRIECcmoBpsnVMbfz7uuAIZY7d_Dt8LLMJZdcUMkG6Po_iHHBeSYZFQN1f6Rw6NvX6EvT1G1tdPOJ3xj-LFkZWEnLl3G3cbaxXwZSwg_WpmK5</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2454416205</pqid></control><display><type>article</type><title>Alvimopan (Entereg) for the Treatment of Postoperative Ileus</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Karuppiah, Sabesan, MD, DFM ; Farrah, Roberta, PharmD, BCPS</creator><creatorcontrib>Karuppiah, Sabesan, MD, DFM ; Farrah, Roberta, PharmD, BCPS</creatorcontrib><description>Alvimopan (Entereg) is an oral, peripherally-acting mu-opioid receptor antagonist used to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection with primary anastomosis.1 Opioids used postoperatively may cause or prolong postoperative ileus. Alvimopan blocks the opioid effect in the gastrointestinal tract without interfering with the central-acting analgesic effects of opioids. Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway.</description><identifier>ISSN: 0002-838X</identifier><identifier>CODEN: AFPYBF</identifier><language>eng</language><publisher>Leawood: American Academy of Family Physicians</publisher><subject>Analgesics ; Antagonist drugs ; Drug dosages ; FDA approval ; Gastrointestinal diseases ; Internal Medicine ; Narcotics ; Patient safety ; Postoperative period ; Surgery</subject><ispartof>American family physician, 2011-04, Vol.83 (8), p.978-979</ispartof><rights>American Family Physician</rights><rights>Copyright American Academy of Family Physicians Apr 15, 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782</link.rule.ids></links><search><creatorcontrib>Karuppiah, Sabesan, MD, DFM</creatorcontrib><creatorcontrib>Farrah, Roberta, PharmD, BCPS</creatorcontrib><title>Alvimopan (Entereg) for the Treatment of Postoperative Ileus</title><title>American family physician</title><description>Alvimopan (Entereg) is an oral, peripherally-acting mu-opioid receptor antagonist used to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection with primary anastomosis.1 Opioids used postoperatively may cause or prolong postoperative ileus. Alvimopan blocks the opioid effect in the gastrointestinal tract without interfering with the central-acting analgesic effects of opioids. Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway.</description><subject>Analgesics</subject><subject>Antagonist drugs</subject><subject>Drug dosages</subject><subject>FDA approval</subject><subject>Gastrointestinal diseases</subject><subject>Internal Medicine</subject><subject>Narcotics</subject><subject>Patient safety</subject><subject>Postoperative period</subject><subject>Surgery</subject><issn>0002-838X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kE9Lw0AUxHNQsFa_w6IXPQQ2-_ZPAiKUUmuhoGAFb2G7eaupaTbubgN-exMq3jw9Bn4zb5iTZEIpZWkO-dtZch7CbpBKZMUkuZs1fb13nW7JzaKN6PH9lljnSfxAsvGo4x7bSJwlzy5E16HXse6RrBo8hIvk1Oom4OXvnSavD4vN_DFdPy1X89k6RSZFTBXLDa8sGIC8UMZKrThjylYWrTBbVUhrskzSSlaCw5aCloCgRIECcmoBpsnVMbfz7uuAIZY7d_Dt8LLMJZdcUMkG6Po_iHHBeSYZFQN1f6Rw6NvX6EvT1G1tdPOJ3xj-LFkZWEnLl3G3cbaxXwZSwg_WpmK5</recordid><startdate>20110415</startdate><enddate>20110415</enddate><creator>Karuppiah, Sabesan, MD, DFM</creator><creator>Farrah, Roberta, PharmD, BCPS</creator><general>American Academy of Family Physicians</general><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20110415</creationdate><title>Alvimopan (Entereg) for the Treatment of Postoperative Ileus</title><author>Karuppiah, Sabesan, MD, DFM ; Farrah, Roberta, PharmD, BCPS</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e265t-728c4df3c33897cf6a74227fdfef5cb796fc1160d6d543b03a63e3759e5380f33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Analgesics</topic><topic>Antagonist drugs</topic><topic>Drug dosages</topic><topic>FDA approval</topic><topic>Gastrointestinal diseases</topic><topic>Internal Medicine</topic><topic>Narcotics</topic><topic>Patient safety</topic><topic>Postoperative period</topic><topic>Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Karuppiah, Sabesan, MD, DFM</creatorcontrib><creatorcontrib>Farrah, Roberta, PharmD, BCPS</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>American family physician</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Karuppiah, Sabesan, MD, DFM</au><au>Farrah, Roberta, PharmD, BCPS</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Alvimopan (Entereg) for the Treatment of Postoperative Ileus</atitle><jtitle>American family physician</jtitle><date>2011-04-15</date><risdate>2011</risdate><volume>83</volume><issue>8</issue><spage>978</spage><epage>979</epage><pages>978-979</pages><issn>0002-838X</issn><coden>AFPYBF</coden><abstract>Alvimopan (Entereg) is an oral, peripherally-acting mu-opioid receptor antagonist used to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection with primary anastomosis.1 Opioids used postoperatively may cause or prolong postoperative ileus. Alvimopan blocks the opioid effect in the gastrointestinal tract without interfering with the central-acting analgesic effects of opioids. Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway.</abstract><cop>Leawood</cop><pub>American Academy of Family Physicians</pub><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-838X |
| ispartof | American family physician, 2011-04, Vol.83 (8), p.978-979 |
| issn | 0002-838X |
| language | eng |
| recordid | cdi_proquest_journals_864645062 |
| source | EZB-FREE-00999 freely available EZB journals |
| subjects | Analgesics Antagonist drugs Drug dosages FDA approval Gastrointestinal diseases Internal Medicine Narcotics Patient safety Postoperative period Surgery |
| title | Alvimopan (Entereg) for the Treatment of Postoperative Ileus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T20%3A34%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_elsev&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Alvimopan%20(Entereg)%20for%20the%20Treatment%20of%20Postoperative%20Ileus&rft.jtitle=American%20family%20physician&rft.au=Karuppiah,%20Sabesan,%20MD,%20DFM&rft.date=2011-04-15&rft.volume=83&rft.issue=8&rft.spage=978&rft.epage=979&rft.pages=978-979&rft.issn=0002-838X&rft.coden=AFPYBF&rft_id=info:doi/&rft_dat=%3Cproquest_elsev%3E2454416205%3C/proquest_elsev%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2454416205&rft_id=info:pmid/&rft_els_id=1_s2_0_S0002838X11601366&rfr_iscdi=true |